Date: 2014-03-16
Type of information: Collaboration agreement
Compound: clinical grade molecular diagnostics using the OncoDEEP DX and Clinical cancer panels
Company: ONcoDNA (Belgium) National Blood and Cancer Center (Saudi Arabia)
Therapeutic area: Diagnostic - Cancer - Oncology
Type agreement:
Action mechanism:
Disease:
Details: * On March 16, 2014, Belgium based OncoDNA, a company providing DNA next generation sequencing (NGS) tests for clinical use in cancer, has announced a supplier agreement with NBCC (National Blood and Cancer Center in Riyadh, Saudi Arabia) to bring affordable and state-of-the-art DNA sequencing technologies to the GCC countries and thus help oncologists make the best decisions in treatment choice. NBCC has chosen OncoDNA as its preferred supplier of clinical grade molecular diagnostics using the OncoDEEP DX and Clinical cancer panels. The collaboration agreement with OncoDNA will enable GCC physicians to access medical innovations based on next gene sequencing, providing them with clinically relevant interpretations of patients\' tumours. OncoDNA’s aim is to provide medical innovations based on targeted sequencing or the complete sequencing of tumour genomes, in order to assist medical doctors in their treatment choices and/or provide better monitoring of the evolution of patient tumours. OncoDNA is a subsidiary of Bio.Be, an affiliated company of IPG (Institute of Pathology and Genetics) in Belgium.
NBCC (National Blood and Cancer Center) is a specialized centre for diagnosing and treating blood diseases and cancers. One of the goals of this private institution is to bring new high value technologies from around the world to Saudi Arabia and its neighbouring countries, at an affordable price.
Financial terms:
Latest news:
